1. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I
- Author
-
Laura D. Attardi, Ciaran M. Lee, Kazuki Sawamoto, Rasmus O. Bak, Laure Aurelian, Rolen M. Quadros, Samantha G. Scharenberg, Matthew H. Porteus, Natalia Gomez-Ospina, Carlos Suárez, Sruthi Mantri, Shaukat Khan, Nitin Raj, Nathalie Mostrel, Shunji Tomatsu, Gang Bao, and Channabasavaiah B. Gurumurthy
- Subjects
0301 basic medicine ,CRISPR-Cas9 genome editing ,Mucopolysaccharidosis I ,CD34 ,PROTEIN ,General Physics and Astronomy ,Antigens, CD34 ,02 engineering and technology ,Mice, SCID ,Iduronidase ,Mice ,Genome editing ,Mice, Inbred NOD ,lcsh:Science ,Gene Editing ,Mice, Knockout ,Multidisciplinary ,Hematopoietic Stem Cell Transplantation ,LYSOSOMAL-ENZYME ,021001 nanoscience & nanotechnology ,3. Good health ,Cell biology ,Haematopoiesis ,Phenotype ,CRISPR-CAS9 ,Stem cell ,0210 nano-technology ,EFFICIENCY ,Receptors, CCR5 ,Science ,Transplantation, Heterologous ,Biology ,GLOBIN GENE ,General Biochemistry, Genetics and Molecular Biology ,Article ,MURINE ,03 medical and health sciences ,Mucopolysaccharidosis type I ,Animals ,Humans ,Progenitor cell ,TRANSPLANTATION ,Genome, Human ,GENE-THERAPY ,General Chemistry ,Genetic Therapy ,Hematopoietic Stem Cells ,Transplantation ,Targeted gene repair ,030104 developmental biology ,NIH 3T3 Cells ,LENTIVIRAL VECTOR ,lcsh:Q ,HURLER-SYNDROME ,CRISPR-Cas Systems - Abstract
Lysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can improve biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. These studies provide support for the development of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes making it applicable to other lysosomal storage disorders., Mucopolysaccharidosis type I (MPSI) is a lysosomal storage disease caused by insufficient iduronidase (IDUA) activity. Here, the authors use an ex vivo genome editing approach to overexpress IDUA in human hematopoietic stem and progenitor cells and show it can phenotypically correct MSPI in mouse model.
- Published
- 2019